The U.S. Food and Drug Administration (FDA) recently approved a needleless anesthetic, Kovanaze.
Kovanaze is administered as an intranasal spray that is a combination of ester anesthetic tetracaine HCI and vasoconstrictor oxymetazoline HCI, making it a regional maxillary anesthesia.
Kovanaze was designed to be used for regional pulpal anesthesia during restoration procedures conducted on teeth 4-13 and A-J in adults and children who weigh at least 88 pounds or more. The anesthesia is administered using a single-use spray that has been prefilled. The spray consists of 0.2 mL, which is made up of 6 mg of tetracaine HCI and 0.1 mg of oxymetazoline HCI.
More information on Kovanaze can be found at www.ada.org.